Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification

被引：2

作者：

Jurmeister, Philipp ^{[1
,2
]}

Bockmayr, Michael ^{[1
,3
]}

Treese, Christoph ^{[4
,5
,6
,7
]}

Stein, Ulrike ^{[5
,6
,8
]}

Lenze, Dido ^{[1
]}

Joehrens, Korinna ^{[1
]}

Friedling, Franziska ^{[9
]}

Dietel, Manfred ^{[1
]}

Klauschen, Frederick ^{[1
]}

Marsch, Wolfgang ^{[9
]}

Fiedler, Eckhard ^{[9
]}

von Laffert, Maximilian ^{[1
,4
]}

机构：

[1] Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany

[2] Charite Comprehens Canc Ctr, Berlin, Germany

[3] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany

[4] BIH, Berlin, Germany

[5] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany

[6] Max Delbruck Ctr Mol Med, Berlin, Germany

[7] Charite Univ Med Berlin, Dept Gastroenterol, Infect Dis, Rheumatol, Campus Benjamin Franklin, Berlin, Germany

[8] German Canc Consortium DKTK, Heidelberg, Germany

[9] Martin Luther Univ Halle Wittenberg, Univ Hosp Halle Saale, Dept Dermatol & Venereol, Halle, Saale, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷 / 08期

关键词：

MALIGNANT-MELANOMA; TRANSCRIPTION FACTOR; TISSUE MICROARRAYS; PROGNOSTIC MARKER; EXPRESSION; SURVIVAL; INVASION; CANCER; WORSE; MET;

D O I：

10.1111/ddg.13917_g

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background and objectives: Overall survival (OS) in patients with early-stage malignant melanoma differs. To date, there are no established prognostic markers. We aimed to contribute to a better understanding of potential prognostic immunohistochemical markers for risk stratification. Patients and methods: 161 surgically resected early-stage malignant melanomas (stage pT1 and pT2) were analyzed for expression of 20 different proteins using immunohistochemistry. The results were correlated with OS. The cohort was randomly split into a discovery and a validation cohort. Results: High Bcl-2 expression, high nuclear S100A4 expression as well as a Ki67 proliferation index of >= 20 % were associated with shorter OS. Strong MITF immunoreactivity was a predictor for favorable prognosis. A combination of these four markers resulted in a multi-marker score with significant prognostic value in multivariate survival analysis (HR: 3.704; 95 % CI 1.484 to 9.246; p = 0.005). Furthermore, the score was able to differentiate a low-risk group with excellent OS rates (five-year survival rate: 100 %), an intermediate-risk group (five-year survival rate: 81.8 %) and a high-risk group (five-year survival rate: 52.6 %). The prognostic value was confirmed within the validation cohort. Conclusions: Combined immunohistochemical analysis of Bcl-2, nuclear S100A4, Ki67 and MITF could contribute to better risk stratification of early-stage malignant melanoma patients.

引用

页码：800 / 809

页数：10

共 1 条

[1] Validation and comparison of CS-IHC4 score with a nomogram based on Ki67 index, Adjuvant! Online, and St. Gallen risk stratification to predict recurrence in early Hormone Receptor (HR)-positive breast cancers
Park, Y. H.
Im, S-A
Cho, E. Y.
Ahn, J. H.
Woo, S. Y.
Kim, S.
Keam, B.
Lee, J. E.
Han, W.
Nam, S. J.
Park, I. A.
Noh, D-Y
Yang, J. H.
Ahn, J. S.
Im, Y-H
CANCER RESEARCH, 2012, 72

← 1 →